According to a report published by the American Diabetes Association, 19% to 34% of patients suffering from diabetes are likely to develop diabetic foot ulcers in their lifetime. According to reports, the yearly incidence of foot ulcers ranges from 1.9% to 4.0%, with higher rates (5.0% to 7.5%). The overall numbers have increased from 9.1 million to 26.1 million individuals globally. Therefore, several companies are heavily investing in developing effective solutions for the disease.
Major companies involved in the diabetic foot ulcers pipeline drugs market include Cytora Ltd, Anterogen Co., Ltd. and Plasmacure among others.
Leading drugs currently under pipeline include allogeneic human oral mucosal stem cells and CYP-006TK among others.
Regulatory authorities such as the United States FDA and EMA play a vital role in the drug pipeline for diabetic foot ulcers as they are offering breakthrough designations and fast-track approvals to several drugs, intended to provide effective treatment to patients.
The Diabetic Foot Ulcers Drug Pipeline Report by Expert Market Research gives comprehensive insights into diabetic foot ulcer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic foot ulcers. The report includes the analysis of over 50 pipeline drugs and 10+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from diabetic foot ulcer.
The detailed analysis of each phase, molecule type, clinical studies, drug type, route of administration and ongoing product development activities related to diabetic foot ulcers are covered.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Diabetic foot ulcer is a serious complication that occurs in patients suffering from diabetes as a result of worsening of the condition which includes high blood sugar levels, nerve damage and poor circulation. The chances of developing diabetic foot ulcers drastically increase because individuals with diabetes are more susceptible to infections due to their compromised immune system. High sugar levels in the blood often result in peripheral neuropathy, resulting in loss of sensation in the feet. In this condition, the body’s natural healing process gets hampered along with the loss of sensation in the feet.
Treatment of diabetic foot ulcers must be specialized for everyone based on the severity. For mild ulcers, first, the wound is cleaned to remove the dead tissues and proper dressing is done to keep the area moist. Advanced wound care products and antibiotics may be necessary for moderate ulcers (if an infection is present). Surgical procedures like skin grafts or vascular surgery may be necessary in cases of severe ulcers along with educating patients on foot care and managing blood glucose levels for all phases of the treatment for efficient management of the disease.
This section of the report covers the analysis of diabetic foot ulcer drugs based on several segmentations including:
By Phase
By Molecule Type
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for diabetic foot ulcer drugs with 278 pipeline drugs in phase III.
The molecule type categories covered under diabetic foot ulcers include monoclonal antibodies, peptides, and small molecules. Out of all the molecule types, monoclonal antibodies are made to attach to proteins or cells that are affected by an infection or inflammation. The report provides a comparative analysis of the different types of molecules.
The EMR report for the diabetic foot ulcers drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic foot ulcers clinical trials:
Leading drugs in the pipeline are as follows:
The trial studies the efficacy of hOMSCs in patients suffering from chronic diabetic foot ulcers. The trial is sponsored by Cytora Ltd. and is currently under phase I/IIa.
The trial studies the efficacy and safety of ALLO-ASC-SHEET in patients suffering from chronic diabetic foot ulcers. The trial is sponsored by Anterogen Co., Ltd. and is currently under phase II.
The trial studies the safety, tolerability and efficacy of CYP-006TK in patients suffering from chronic diabetic foot ulcers. The trial is currently under phase I and is sponsored by Cynata Therapeutics.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Diabetic foot ulcers Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic foot ulcers. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within diabetic foot ulcers pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Molecule Type |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share